Novartis was expecting a lot from its PARAGON-HF trial of Entresto in heart failure with preserved ejection fraction (HFpEF) and isn’t letting a missed endpoint scupper the programme.

In the phase III trial, which was stopped early, Entresto proved superior to the ACE inhibitor enalapril, reducing the risk of cardiovascular death or heart failure hospitalisation by 20 per cent ...